BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC

Effectively treating KRAS-driven tumors remains an unsolved challenge. The inhibition of downstream signaling effectors is a way of overcoming the issue of direct targeting of mutant KRAS, which has shown limited efficacy so far. Bromodomain and Extra-Terminal (BET) protein inhibition has displayed...

Descripción completa

Detalles Bibliográficos
Autores principales: Jauset, Toni, Massó-Vallés, Daniel, Martínez-Martín, Sandra, Beaulieu, Marie-Eve, Foradada, Laia, Fiorentino, Francesco Paolo, Yokota, Jun, Haendler, Bernard, Siegel, Stephan, Whitfield, Jonathan R., Soucek, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922351/
https://www.ncbi.nlm.nih.gov/pubmed/29721157
http://dx.doi.org/10.18632/oncotarget.24648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922351/
https://www.ncbi.nlm.nih.gov/pubmed/29721157
http://dx.doi.org/10.18632/oncotarget.24648

Ejemplares similares